In an industry known for pushing the bounds of human innovation, tech elites are now trying to push the bounds of their own bodies. The hot new biohacking trend is injectable peptides — similar to the ones found in GLP-1 medications like Ozempic. But these are not approved by the Food and Drug Administration.
These gray-market peptides, largely from Chinese manufacturers, are being used by tech workers and founders. Not just to lose weight, but to optimize their health and performance in all manner of ways. “Marketplace Tech” host Meghan McCarty Carino speaks with independent journalist Jasmine Sun, who recently wrote about this for the New York Times.
